Cefamandole nafate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Cefamandole nafate
Accession Number
DB14725
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • O-formylcefamandole
Product Ingredients
IngredientUNIICASInChI Key
Cefamandole nafate sodium8HDO7941DO42540-40-9ICZOIXFFVKYXOM-YCLOEFEOSA-M
Active Moieties
NameKindUNIICASInChI Key
Cefamandoleprodrug5CKP8C2LLI34444-01-4OLVCFLKTBJRLHI-AXAPSJFSSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mandol Inj 1gm/ampPowder, for solution1 gIntramuscular; IntravenousEli Lilly & Co. Ltd.1978-12-312000-10-02Canada
Mandol Inj 2gm/ampPowder, for solution2 gIntravenousEli Lilly & Co. Ltd.1978-12-312000-08-03Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Kefadol (Lilly) / Kefandol (Lilly) / Mandokef (Lilly) / Mandol (Lilly)
Categories
UNII
Not Available
CAS number
57268-80-1
Weight
Average: 490.51
Monoisotopic: 490.072924672
Chemical Formula
C19H18N6O6S2
InChI Key
RRJHESVQVSRQEX-SUYBPPKGSA-N
InChI
InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1
IUPAC Name
(6R,7R)-7-[(2R)-2-(formyloxy)-2-phenylacetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](OC=O)C1=CC=CC=C1)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Cefamandole nafate is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Cefamandole nafate is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Cefamandole nafate is combined with 4-hydroxycoumarin.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefamandole nafate is combined with Acenocoumarol.
Acetylsalicylic acidThe therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Cefamandole nafate.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Cefamandole nafate.
AlteplaseThe therapeutic efficacy of Alteplase can be decreased when used in combination with Cefamandole nafate.
AmediplaseThe therapeutic efficacy of Amediplase can be decreased when used in combination with Cefamandole nafate.
AnagrelideThe therapeutic efficacy of Anagrelide can be decreased when used in combination with Cefamandole nafate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
4447585
ChEBI
53654
ChEMBL
CHEMBL1201218
Wikipedia
Cefamandole

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Powder, for solutionIntramuscular; Intravenous1 g
Powder, for solutionIntravenous2 g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.227 mg/mLALOGPS
logP0.61ALOGPS
logP0.42ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.1ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area156.61 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity131.31 m3·mol-1ChemAxon
Polarizability45.27 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on December 14, 2018 10:21 / Updated on May 01, 2019 13:35